TISSUE & FFPE COHORT COLLECTIONS

Lung cancer tissue microarrays & FFPE blocks

Explore NSCLC and SCLC arrays by histology, molecular profile and treatment context. Compare adenocarcinoma and squamous cell carcinoma collections, matched tissue, and selected clinical or molecular datasets. For FFPE blocks, share your tissue and study requirements with our team.

THE ARRAYS

Lung cancer arrays (53)

Collection types in this TMA catalog

Explore the tissue composition and sampling groups represented in these arrays.

Data labels reflect the catalog record. Review each product and datasheet for case-level coverage. Array counts do not indicate stock availability.

FFPE TISSUE BLOCKS

Lung cancer FFPE blocks for your study

NSCLC cohorts with histopathology, EGFR/KRAS, PD-L1, treatment, matching or optional datasets.

FFPE blocks are requested by inquiry. Our team confirms tissue availability, donor matching and data coverage for your study.

FFPE TISSUE COHORTS

Lung cancer FFPE cohorts

Select a cohort or patient profile, then share your sample and data requirements with our team.

Cohort #111

NSCLC (ADC & SCC) primary & matched nodal mets

Cohort #112

NSCLC (ADC & SCC) stage III/IV with follow up data

Cohort #113

NSCLC (ADC & SCC) stages IIIA, IIIB & IV with histopath data

Cohort #115

NSCLC (ADC & SCC) with follow up data

Cohort #117

NSCLC (ADC & SCC) with low, moderate & high PD-L1(22C3) expression with histopath data - optional follow up data

Cohort #118

NSCLC (ADC) with follow up, PD-L1(22C3) & MSI data

Cohort #119

NSCLC (EGFR mutated & wild type) with histopath data

Cohort #120

NSCLC (KRAS mutated & wild type) with histopath data

Cohort #121

NSCLC with histopath data & (PD-L1) scores 22C3

Cohort #122

NSCLC (SCC) with histopath data

Cohort #127

NSCLC post-treatment samples with follow up, KRAS & EGFR mutation data

Cohort #128

NSCLC primary & matched nodal mets with histopath data

Cohort #131

NSCLC with EGFR mutations & histopath data

Cohort #132

NSCLC with EGFR mutations & follow up data

Cohort #134

NSCLC with KRAS & EGFR mutation data

Cohort #135

NSCLC with KRAS mutations status

Cohort #136

NSCLC with SOC chemo follow up & optional GeoMx (protein panel) data

Cohort #137

NSCLC with TKI responders/non responders & follow up data

Cohort #138

NSCLC with histopath data & matched plasma

NSCLC · Patient profile

EGFR-mutated locally advanced or metastatic disease

NSCLC · Patient profile

EGFR-mutated, MET-positive locally advanced or metastatic disease

NSCLC · Patient profile

EGFR exon 20 insertion mutation

NSCLC · Patient profile

TKI-treatment-naïve ROS1-positive disease

NSCLC · Patient profile

Advanced or metastatic NSCLC

NSCLC · Patient profile

PD-L1 <50% metastatic NSCLC

NSCLC · Patient profile

PD-L1 tumor-cell expression ≥1% non-squamous NSCLC

NSCLC · Patient profile

PD-L1 tumor-cell expression ≥1% squamous NSCLC

NSCLC · Patient profile

PD-L1 tumor-cell expression ≥50% locally advanced or metastatic non-squamous NSCLC

NSCLC · Patient profile

Before or after immunotherapy / checkpoint inhibitor treatment

Small-cell lung cancer · Patient profile

Relapsed / refractory small-cell lung cancer

Small-cell lung cancer · Patient profile

Extensive-stage small-cell lung cancer

SELECTING YOUR ARRAY

Match lung histology, markers and treatment context

A marker-defined array and a treatment-follow-up array answer different selection needs. Review the tissue and the associated records together.

TA2820 tissue composition

NSCLC TMA with KRAS mutations (TA2820).

TA2826 tissue composition

NSCLC TMA with EGFR mutations (TA2826).

TA2855 tissue composition

NSCLC (ADC) with follow up, PD-L1(22C3) & MSI data.